Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

1.61
-0.0100-0.62%
Post-market: 1.60-0.0100-0.62%19:57 EDT
Volume:435.09K
Turnover:707.13K
Market Cap:77.78M
PE:-1.10
High:1.67
Open:1.64
Low:1.60
Close:1.62
Loading ...

Cassava Sciences Shares Fall 14.3% Premarket After Co to Discontinue Development of Alzheimer's Disease Drug

THOMSON REUTERS
·
25 Mar

Cassava Sciences' controversial Alzheimer's drug fails in second late-stage study

Reuters
·
25 Mar

Cassava to discontinue development of Alzheimer's disease drug

Reuters
·
25 Mar

Cassava Sciences Reports Topline Phase 3 Refocus-Alz Data

THOMSON REUTERS
·
25 Mar

Cassava Sciences Inc - Refocus-Alz Study Did Not Meet Primary, Secondary, or Exploratory Endpoints

THOMSON REUTERS
·
25 Mar

Cassava Sciences Inc - to Discontinue Alzheimer's Program With Simufilam by End of Q2 2025

THOMSON REUTERS
·
25 Mar

Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data

GlobeNewswire
·
25 Mar

Chinese Drug Administration Accepts Application of Centergate Technologies' Unit for Oxycodone Hydrochloride Tablets

MT Newswires Live
·
14 Mar

Cassava Sciences Amends Bonus Plan After Court Settlement

TIPRANKS
·
12 Mar

Cassava Sciences (SAVA) Upgraded to Buy: What Does It Mean for the Stock?

Zacks
·
08 Mar

H.C. Wainwright Sticks to Their Hold Rating for Cassava Sciences (SAVA)

TIPRANKS
·
05 Mar

H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal

TIPRANKS
·
05 Mar

Protega Pharmaceuticals collaborates with Wellgistics to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

GlobeNewswire
·
04 Mar

Cassava Sciences Reports 2024 Financial Results and Strategic Updates

TIPRANKS
·
04 Mar

Cassava Sciences Q4 2024 GAAP EPS $(0.57) Beats $(0.66) Estimate, $128.6M In Cash And Cash Equivalents

Benzinga
·
03 Mar

BRIEF-Cassava Sciences Q4 Basic EPS USD -0.57

Reuters
·
03 Mar

Cassava Sciences Q4 Operating Expenses USD 29.487 Million

THOMSON REUTERS
·
03 Mar

Cassava Sciences Q4 Basic EPS USD -0.57

THOMSON REUTERS
·
03 Mar

Cassava Sciences Reports 2024 Financial Results and Provides Business Update

GlobeNewswire
·
03 Mar

Sector Update: Health Care Stocks Softer Late Afternoon

MT Newswires Live
·
28 Feb